InMed Pharmaceuticals is developing a gel-based cannabinoid drug for eye diseases such as glaucoma, which it says could be cheaper and more accessible than cannabinoid-based products on the market.
Articles
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration
GW Pharmaceuticals completes the rolling submission of a new drug to the FDA for treatment of two forms of childhood-epilepsy.
Oregon Overhauls its Approach to Industrial Hemp
Passage of a new law in Oregon that requires industrial hemp growers to register with the state is seen as a positive move for the industry, advocates of the program are saying.
Canada Is Set To Become The World's Weed Dealer
As it gets set to become the world's first legal recreational marijuana market, Canada is gearing up to be the main exporter for pot worldwide.
INMED PHARMACEUTICALS (CSE: IN; OTCMKTS: IMLFF) Could Be Poised For Gains
InMed Pharmaceuticals is a turnaround stock, with recent news updates showing promise for future gains
Biosynthetic cannabinoids could be the way of the future
InMed Pharmaceuticals develops technology to bridge the gap between synthetic and natural cannabinoids.
New Cannabinoid Medicine Can Be Successfully Administered Via a Topical Gel Eye Lens
New cannabinoid medicine can be successfully administered via a topical gel lens into the eye, a new InMed-University of British Columbia study reports.
Marijuana Company of America (MCOA) Delivers Distinctive Cannabis Investment Opportunities
Marijuana Company of America (OTC: MCOA) is a distinctive corporation utilizing a strategic business structure within this burgeoning industry.
Grey Cloak Tech, Inc. (GRCK) Announces Cancellation of Reverse Stock Split
Grey Cloak Tech, Inc. (OTCQB: GRCK) today announced that its board of directors has decided to abandon and cancel the reverse stock split that was previously approved by both the board and the company’s shareholders in February 2017.
SinglePoint, Inc. (SING) President Discusses Acquisitions, Cannabis and Cryptocurrency in New Podcast Interview
Specialized holding company SinglePoint, Inc. (OTC: SING) is the focus of a newly-released podcast interview announced this morning by Investorideas.com.
InMed (CSE: IN; OTCQB: IMLFF) Uses Expertise to Create Shareholder Value
Looking at how the expertise of InMed's management, consulting and advisory team combines to drive value for shareholders.
Global Payout, Inc. (GOHE) Subsidiary Ramping-Up Sales and Marketing Efforts for PotSaver Brand
Payment solutions company Global Payout, Inc. (OTC: GOHE) this morning announced that its majority owned subsidiary, MoneyTrac Technology, Inc., is currently in the process of ramping-up its sales and marketing efforts within Los Angeles County for its newly-acquired PotSaver brand.
BCC Provides Update on Health Canada Licensed Producer Application and Owen Sound Facility Build Out
7,700 kg per annum facility to focus on high-margin concentrates, leveraging award-winning MPX brand.
Canopy Growth increases international footprint by expanding into Jamaican medical market with the introduction of Tweed JA
Canopy Growth Corporation (TSX: WEED) is pleased to announce that it has launched a strategic partnership in the Jamaican cannabis market as part of its ongoing international expansion.
Why InMed's (CSE: IN; OTCQB: IMLFF) Ground Breaking Biosynthesis Program Adds Investor Value
We think that InMed’s proprietary technology could put $6.6 Billion in play and make it one of the strongest biotech stocks in the market. We also think InMed is in the right place at the right time to create real value for investors in the Industry. Here's a few reasons why.